HON vs PFE: Which Is the Better Buy?
Side-by-side comparison of Honeywell International Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-14.
Honeywell International Inc. · Industrials
$222.25
-5.5% upside to fair value
Grade D
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+2.8%).
HON trades at a lower forward P/E
(15.7x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
HON |
PFE |
| Current Price |
$222.25 |
$25.22 |
| Fair Value Estimate |
$210.05 |
$25.92 |
| Upside to Fair Value |
-5.5%
|
+2.8%
|
| Market Cap |
$70.4B |
$143.7B |
| Forward P/E |
15.7x
|
19.2x
|
| EV / EBITDA |
13.1x
|
12.3x
|
| Price / Sales |
1.9x
|
2.3x
|
| Price / FCF |
17.1x
|
15.2x
|
| Revenue Growth YoY |
-6.9%
|
+5.4%
|
| Gross Margin |
36.9%
|
69.3%
|
| Operating Margin |
14.9%
|
23.4%
|
| Return on Equity |
23.6%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.84%
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Honeywell International Inc. operates as a diversified industrial conglomerate with a strong presence in multiple sectors including aerospace, building technologies, and performance materials. The company demonstrates high business quality with a durable competitive moat supported by strong margins, a 23.6% return on equity, and solid free cash flow generation of $16.78 per share. However, recent…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
HON |
PFE |
| Zone Low |
$157.54 |
$19.44 |
| Zone High |
$178.54 |
$22.03 |
| In Buy Zone? |
No
|
No
|